Tealwood Asset Management Inc. Purchases 8,694 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Tealwood Asset Management Inc. raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 19.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,813 shares of the biopharmaceutical company’s stock after acquiring an additional 8,694 shares during the period. Halozyme Therapeutics makes up 1.0% of Tealwood Asset Management Inc.’s portfolio, making the stock its 28th biggest holding. Tealwood Asset Management Inc.’s holdings in Halozyme Therapeutics were worth $2,525,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Congress Asset Management Co. boosted its stake in Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after purchasing an additional 1,988,238 shares during the period. Handelsbanken Fonder AB boosted its position in shares of Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after acquiring an additional 856,200 shares during the period. Boston Trust Walden Corp grew its stake in shares of Halozyme Therapeutics by 54.0% in the third quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock worth $39,073,000 after acquiring an additional 239,321 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after acquiring an additional 209,530 shares during the period. Finally, South Street Advisors LLC acquired a new position in Halozyme Therapeutics during the 3rd quarter valued at $9,812,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Up 2.5 %

Shares of NASDAQ:HALO opened at $54.14 on Tuesday. The company’s fifty day moving average is $50.14 and its 200-day moving average is $54.03. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The company has a market capitalization of $6.89 billion, a PE ratio of 17.93, a P/E/G ratio of 0.44 and a beta of 1.24.

Analysts Set New Price Targets

Several analysts have issued reports on HALO shares. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday. Wells Fargo & Company cut their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday. JMP Securities boosted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.